O(6)-Benzylguanine in Treating Patients With Malignant Glioma

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of O(6)-benzylguanine given before surgery to patients who have malignant glioma.

Key facts

Study ID

NCT00002971

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Starts

1997-06-19

Expected to finish

2009-01-01

Last updated by the study team

2018-06-27

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
• Simmons Cancer Center - Dallas — Dallas, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.